KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
14.34
-1.17 (-7.54%)
Jul 11, 2025, 10:09 AM - Market open

KalVista Pharmaceuticals Income Statement

Millions USD. Fiscal year is May - Apr.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2016 - 2020
Period Ending
Apr '25 Apr '24 Apr '23 Apr '22 Apr '21 2016 - 2020
Cost of Revenue
71.7186.1780.2870.1741.29
Upgrade
Gross Profit
-71.71-86.17-80.28-70.17-41.29
Upgrade
Selling, General & Admin
116.2954.2830.626.4516.64
Upgrade
Operating Expenses
116.2954.2830.626.4516.64
Upgrade
Operating Income
-188-140.45-110.87-96.61-57.92
Upgrade
Interest Expense
-5.79----
Upgrade
Interest & Investment Income
6.443.92.231.090.9
Upgrade
Currency Exchange Gain (Loss)
2.480.140.09-1.540.85
Upgrade
Other Non Operating Income (Expenses)
4.818.4415.7815.39.93
Upgrade
EBT Excluding Unusual Items
-180.05-127.97-92.77-81.76-46.24
Upgrade
Gain (Loss) on Sale of Investments
-1.33-0.14-0.58-
Upgrade
Pretax Income
-180.05-126.64-92.91-82.34-46.24
Upgrade
Income Tax Expense
3.39----
Upgrade
Net Income
-183.44-126.64-92.91-82.34-46.24
Upgrade
Net Income to Common
-183.44-126.64-92.91-82.34-46.24
Upgrade
Shares Outstanding (Basic)
5037282419
Upgrade
Shares Outstanding (Diluted)
5037282419
Upgrade
Shares Change (YoY)
34.98%31.89%13.96%28.17%7.58%
Upgrade
EPS (Basic)
-3.69-3.44-3.33-3.36-2.42
Upgrade
EPS (Diluted)
-3.69-3.44-3.33-3.36-2.42
Upgrade
Free Cash Flow
--89.27-76.46-79.07-30.25
Upgrade
Free Cash Flow Per Share
--2.43-2.74-3.23-1.58
Upgrade
EBITDA
-187.09-139.63-110.15-96.05-57.39
Upgrade
D&A For EBITDA
0.910.820.720.560.54
Upgrade
EBIT
-188-140.45-110.87-96.61-57.92
Upgrade
Updated Jul 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q